Allspring Global Investments Holdings LLC Has $1.21 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Allspring Global Investments Holdings LLC boosted its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 6.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,943 shares of the company’s stock after buying an additional 3,837 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.09% of Kiniksa Pharmaceuticals worth $1,212,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of KNSA. New York State Common Retirement Fund grew its position in shares of Kiniksa Pharmaceuticals by 148.6% in the fourth quarter. New York State Common Retirement Fund now owns 34,867 shares of the company’s stock valued at $612,000 after purchasing an additional 20,841 shares during the last quarter. Victory Capital Management Inc. increased its position in Kiniksa Pharmaceuticals by 45.0% in the 4th quarter. Victory Capital Management Inc. now owns 14,653 shares of the company’s stock worth $257,000 after buying an additional 4,547 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Kiniksa Pharmaceuticals by 11.4% during the fourth quarter. BNP Paribas Financial Markets now owns 76,668 shares of the company’s stock worth $1,345,000 after buying an additional 7,846 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $951,000. Finally, QRG Capital Management Inc. grew its stake in shares of Kiniksa Pharmaceuticals by 11.7% in the fourth quarter. QRG Capital Management Inc. now owns 16,010 shares of the company’s stock worth $281,000 after acquiring an additional 1,679 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Four analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $32.00.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the transaction, the insider now owns 52,038 shares in the company, valued at $1,359,232.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 22,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $26.32, for a total transaction of $579,040.00. Following the completion of the transaction, the insider now directly owns 47,803 shares of the company’s stock, valued at $1,258,174.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the sale, the insider now directly owns 52,038 shares in the company, valued at approximately $1,359,232.56. The disclosure for this sale can be found here. Insiders have sold a total of 260,564 shares of company stock valued at $6,727,929 over the last quarter. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ:KNSA opened at $25.74 on Thursday. The firm has a market capitalization of $1.83 billion, a PE ratio of 234.02 and a beta of 0.38. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $14.12 and a 1-year high of $27.92. The business’s 50 day moving average is $23.90 and its 200-day moving average is $20.85.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The firm had revenue of $108.30 million for the quarter, compared to the consensus estimate of $90.60 million. During the same quarter in the previous year, the company earned ($0.02) earnings per share. The business’s revenue was up 51.5% compared to the same quarter last year. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.06 EPS for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.